My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Reliance Capital gains after board approves independent listing of home finance business

Reliance Capital gains after board approves independent listing of home finance business

Sep 14,2016

The announcement was made yesterday, 13 September 2016, when stock market remained closed on account of Bakri Id.

Meanwhile, the S&P BSE Sensex was down 46.19 points or 0.16% at 28,307.35.

On BSE, so far 6.75 lakh shares were traded in the counter as against average daily volume of 5.01 lakh shares in the past one quarter. The stock hit a high of Rs 561.50 and a low of Rs 546.65 so far during the day. The stock had hit a 52-week high of Rs 574 on 9 September 2016. The stock had hit a 52-week low of Rs 303.60 on 12 February 2016. The stock had outperformed the market over the past one month till 12 September 2016, rising 21.96% compared with 0.71% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 32.06% as against Sensexs 6.45% rise.

The large-cap company has equity capital of Rs 252.63 crore. Face value per share is Rs 10.

Reliance Capital said the independent listing of Reliance Home Finance (RHF) is expected to unlock substantial value for existing shareholders of Reliance Capital. The listing of Reliance Home Finance will also lead to increased management focus and accelerated growth in the home finance business. As per the proposal, 49% stake in Reliance Home Finance Limited will be allotted to all shareholders of Reliance Capital, in the ratio of one share free of cost in Reliance Home Finance for every one share held in Reliance Capital.

Reliance Capital will hold a 51% stake in Reliance Home Finance, and the company will be adequately capitalised to grow the lending book to over Rs 20000 crore in the next 18 months. The proposal is subject to necessary shareholders and other approvals. Reliance Home Finance, a 100% subsidiary of Reliance Capital, provides a wide range of loan solutions like home loan, LAP, construction finance and affordable housing loans. The company reported an AUM of Rs 8259 crore ($1.2 billion) during the quarter ended 30 June 2016.

Mr. Anmol A. Ambani, Director, Reliance Capital said Prime Minister, Narendra Modi has set a goal of affordable housing for all by 2022. There is presently an estimated shortage of 10 crore residential units in India. To address the needs of this sector, Reliance Home Finance has charted an aggressive growth plan in this space, and aims to increase its book size to over Rs 50000 crore in the next few years.

On a consolidated basis, Reliance Capitals net profit rose 3% to Rs 207 crore on 48.3% growth in total income to Rs 3663 crore in Q1 June 2016 over Q1 June 2015.

Reliance Capital, a part of the Reliance Group, is one of Indias leading private sector financial services companies.

Powered by Capital Market - Live News

Shriram Transport Finance Company allots NCDs aggregating Rs 140 crore
Feb 27,2017

Shriram Transport Finance Company announced that the Allotment Committee - NCDs of the Company in its meeting held on 27 February 2017, approved and allotted 1400 Secured Redeemable Rated Listed Non-Convertible Debenture of face value of Rs. 10,00,000/- (Rupees Ten Lakh only) each, aggregating to Rs. 140 crore on private placement basis.

Powered by Capital Market - Live News

Bharti Airtel announces value propositions for domestic and international roaming
Feb 27,2017

Bharti Airtel has announced new proposition for domestic and international roaming. From 01 April 2017, Airtel customers roaming in India will enjoy free incoming calls/SMS and there will be no premium on outgoing calls within the country. Also, there will be no additional data charges on national roaming.

From 01 April 2017, Airtel customers on international roaming Without a Pack will be fully protected from bill shocks through an automatic adjustment that is equal to the daily pack for that particular country. This means that the moment a customers billing reaches the price of a one day pack for that country, he/she will be automatically moved to that pack.

Powered by Capital Market - Live News

Vesuvius India to hold AGM
Feb 27,2017

Vesuvius India announced that the th Annual General Meeting(AGM) of the company on 12 May 2017.

Powered by Capital Market - Live News

Welterman International to hold board meeting
Feb 27,2017

Welterman International will hold a meeting of the Board of Directors of the Company on 28 February 2017.

Powered by Capital Market - Live News

Board of Vesuvius India recommends final dividend
Feb 27,2017

Vesuvius India announced that the Board of Directors of the Company at its meeting held on 27 February 2017, inter alia, have recommended the final dividend of Rs 6.5 per equity Share (i.e. 65%) , subject to the approval of the shareholders.

Powered by Capital Market - Live News

Simplex Papers director resigns
Feb 27,2017

Simplex Papers announced that K. C. Murarka, Non-Executive Independent Director of the Company has tendered his resignation with effect from the close business hours of 27 February 2017.

Powered by Capital Market - Live News

Corporation Bank intimates of bank strike
Feb 27,2017

Corporation Bank announced that the Bank has been informed by the Indian Banks Association vide their Circular letter dated 13 February 2017 that the members of all constituent unions of United Forum of Bank Unions (UFBU) working in various offices/branches of Public Sector Banks in India may take part in the proposed one day strike on 28 February 2017, in support of some of their demands. In view of this, the normal functioning of the Banks Branches may get affected.

Powered by Capital Market - Live News

Corporation Bank intimates of bank strike
Feb 27,2017

Corporation Bank announced that the Bank has been informed by the Indian Banks Association vide their Circular letter dated 13 February 2017 that the members of all constituent unions of United Forum of Bank Unions (UFBU) working in various offices/branches of Public Sector Banks in India may take part in the proposed one day strike on 28 February 2017, in support of some of their demands. In view of this, the normal functioning of the Banks Branches may get affected.

Powered by Capital Market - Live News

Adani Ports & Special Economic Zone gets reaffirmation of credit ratings
Feb 27,2017

Adani Ports & Special Economic Zone announced that ICRA has re-affirmed its AA+ rating for Bank Limits and Non-Convertible Debentures. The outlook has been revised upwards from negative to STABLE. ICRA has re-affirmed its A1+ rating (Top notch) for the Commercial Papers Programme of the Company.

Powered by Capital Market - Live News

Adani Ports & Special Economic Zone gets reaffirmation of credit ratings
Feb 27,2017

Adani Ports & Special Economic Zone announced that ICRA has re-affirmed its AA+ rating for Bank Limits and Non-Convertible Debentures. The outlook has been revised upwards from negative to STABLE. ICRA has re-affirmed its A1+ rating (Top notch) for the Commercial Papers Programme of the Company.

Powered by Capital Market - Live News

Goldstone Infratech jumps on big order for pure electric buses
Feb 27,2017

The announcement was made during market hours today, 27 February 2017.

Meanwhile, the S&P BSE Sensex was down 91.96 points or 0.32% at 28,801.01.

On the BSE, 66,000 shares were traded on the counter so far as against the average daily volumes of 50,967 shares in the past one quarter. The stock had hit a high of Rs 47.85 and a low of Rs 46.50 so far during the day.

The stock had hit a 52-week high of Rs 51.50 on 21 February 2017 and a 52-week low of Rs 15.45 on 28 March 2016. It had outperformed the market over the past one month till 23 February 2017, surging 61.7% compared with the Sensexs 6.55% rise. The scrip had also outperformed the market over the past one quarter, advancing 77.43% as against the Sensexs 10.91% rise.

The small-cap company has equity capital of Rs 14.43 crore. Face value per share is Rs 4.

Goldstone Infratech announced that it has bagged its second order for supply of twenty five pure electric buses to Himachal Road Transport Corporation (HRTC), Shimla, at a price of Rs 47.75 crore excluding AMC charges.

Goldstone has successfully completed trials of Midi electric bus in Manali-Rohtang pass. Goldstone shall be assembling these buses in India in tie up with BYD Auto, China. The bus will be designed in India and the bus body shall be fully built in India, the company said.

Goldstone Infratech had received its first order for supply of six pure electric buses to Brihan Mumbai Electricity Supply and Transport (BEST) undertaking, Mumbai.

Goldstone Infratechs net profit rose 35.6% to Rs 1.18 crore on 29.7% growth in net sales to Rs 23.35 crore in Q3 December 2016 over Q3 December 2015.

Goldstone Infratech is one of leading manufacturers for silicone rubber insulators for power transmission and distribution networks and supplies to large transmission & distribution companies and railways/metro rails in India and overseas.

Powered by Capital Market - Live News

Goa Carbon temporarily shuts down Goa plant
Feb 27,2017

Goa Carbon announced that the operations at the Companys Goa Plant located at St. Jose de Areal, Salcete-Goa, has been temporarily shut down from 27 February 2017.

There would not be any financial impact due to the temporary shutdown of the Companys Goa Unit as there are adequate finished, product inventories to service the orders in hand.

Powered by Capital Market - Live News

Vesuvius India fixes record date of dividend
Feb 27,2017

Vesuvius India has fixed 05 May 2017 as the Record Date for the purpose of determining those Members who will be entitled to dividend & the 26th Annual General Meeting (AGM) of the Company to be held on 12 May 2017.

Powered by Capital Market - Live News

Cadila Healthcare gains after receiving USFDA approval for anti viral drug
Feb 27,2017

The announcement was made during market hours today, 27 February 2017.

Meanwhile, the S&P BSE Sensex was down 22.92 points or 0.08% at 28,870.05.

On the BSE, 93,437 shares were traded on the counter so far as against the average daily volumes of 1.05 lakh shares in the past one quarter. The stock had hit a high of Rs 443 and a low of Rs 432.50 so far during the day. The stock had hit a record high of Rs 460 on 17 February 2017. The stock had hit a 52-week low of Rs 305 on 12 April 2016.

The stock had outperformed the market over the past one month till 23 February 2017, advancing 20.45% compared with the Sensexs 6.55% rise. The scrip had, however, underperformed the market over the past one quarter, gaining 9.69% as against the Sensexs 10.91% rise.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare announced that Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the United States Food & Drug Administration (USFDA) to market Oseltamivir Phosphate Capsules, USP in strengths of 30mg, 45mg and 75mg.

The drug will be produced at the Nesher Pharmaceuticals USA manufacturing facility located at St. Louis, MO, USA. It is an anti viral used in the prevention and treatment of influenza virus infection. The estimated sales of capsules was $382 million as per IMS December 2016 data.

The group has also received the final approval from the USFDA to market Linezolid Tablets USP, 600 mg. The drug is an anti-bacterial agent used to treat certain serious bacterial infections and will be produced at the groups formulations manufacturing facility in the Pharma SEZ in Ahmedabad.

Cadila Healthcares consolidated net profit fell 34.6% to Rs 281.60 crore on 0.8% decrease in net sales to Rs 2249.60 crore in Q3 December 2016 over Q3 December 2015.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Jubilant Life Sciences gains on USFDA nod for generic drug
Feb 27,2017

The announcement was made during market hours today, 27 February 2017.

Meanwhile, the S&P BSE Sensex was almost unchanged at 28,893.03.

On the BSE, 63,000 shares were traded on the counter so far as against the average daily volumes of 1.37 lakh shares in the past one quarter. The stock had hit a high of Rs 728 and a low of Rs 704 so far during the day.

The stock had hit a record high of Rs 765 on 7 February 2017 and a 52-week low of Rs 287.20 on 29 February 2016. It had underperformed the market over the past one month till 23 February 2017, gaining 4.7% compared with the Sensexs 6.55% rise. The scrip had also underperformed the market over the past one quarter, advancing 8.83% as against the Sensexs 10.91% rise.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Rs 1.

ltraconazole Capsules, 100 mg, is the generic version of Sporanox of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.

Jubilant Life Sciences has received 8 approvals from the United States Food and Drug Administration (USFDA) during the year. As on 31 December 2016, Jubilant Life Sciences had a total of 73 abbreviated new drug application (ANDAs) for oral solids filed in the US, of which 49 have been approved.

On a consolidated basis, Jubilant Life Sciences net profit fell 2.6% to Rs 119.78 crore on 8.7% growth in net sales to Rs 1438.81 crore in Q3 December 2016 over Q3 December 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma, is engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.

The life science ingredients segment, is engaged in specialty intermediates, nutritional products and life science chemicals through 5 manufacturing facilities in India. The drug discovery solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA.

Powered by Capital Market - Live News